Advertisement
Product › Details
netupitant
Next higher product group | pharmaceutical_oo | |
Status | 2014-01-01 registration start | |
Organisation | Roche (Group) | |
Person | Hoffmann, Torsten (Taros Chemicals 201810– SVP Drug Discovery before Silence Therapeutics + Zealand Pharma + Roche) | |
Silence Therapeutics plc. (6/1/17). "Press Release: Hiring of Chief Operating Officer".
Silence Therapeutics plc, AIM:SLN (“Silence” or “the Company”) a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces the hiring of Torsten Hoffmann as Chief Operating Officer, reporting directly to Ali Mortazavi, Chief Executive Officer. This is not a plc board appointment.
Torsten is joining Silence from Proteros biostructures where he served as Chief Scientific Officer and Managing Director from July 2015, and before then as Chief Scientific Officer and Executive Vice President at Zealand Pharma from July 2013. Prior to that, he spent 16 years at Roche in roles of increasing responsibility up to Site Head of Medicinal Chemistry, and Head of the Global Roche Postdoc fellowship program. Torsten is the lead inventor of netupitant, discovered at Roche and approved by the FDA as Akynzeo© in 2014.
Torsten has a Ph.D. in Chemistry from the ETH Zürich, Switzerland, which was followed by a role as research associate with Professor Richard A. Lerner at the Scripps Research Institute in La Jolla, California. He has authored more than 85 publications, patent applications and published conference reports, has served on advisory boards, and his awards include the Feodor Lynen award and fellowship from the Alexander von Humboldt Foundation, Germany.
Ali Mortazavi, Chief Executive Officer of Silence Therapeutics, commented:
“I am delighted that Torsten has joined Silence at this pivotal time for the company. As we continue to make progress with our new GalNAc-based platform, Torsten brings an experienced rigour to our operations with his knowledge from target selection through to clinical trials. I have been impressed with his energy and the way that he has quickly formed a close working relationship with our Chief Scientific Officer, Dmitry Samarsky. As a consultant, he has already enabled us to drive efficiency through outsourcing certain activities and he will add further immediate benefits in the field of gene target selection and novel RNA therapeutics, helping to further differentiate Silence in delivering high quality medicines for better patients’ lives.”
Enquiries:
Silence Therapeutics plc
Ali Mortazavi, Chief Executive Officer
David Ellam, Chief Financial Officer
Tel: +44 (0)20 3457 6900
Canaccord Genuity Limited (Nominated Adviser and Joint Broker)
Henry Fitzgerald-O'Connor/Emma Gabriel
Tel: +44 (0)20 7523 8350
Peel Hunt LLP (Joint Broker)
James Steel/Oliver Jackson
Tel: +44 (0)20 7418 8900
Media Enquiries:
Tel: +44 (0) 20 3727 1000
FTI Consulting
Simon Conway/Brett Pollard/Stephanie Cuthbert
Notes to Editors
About Silence Therapeutics plc
Silence Therapeutics develops a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, within its cells. Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence’s proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.
Record changed: 2023-07-10 |
Advertisement
More documents for pharmaceutical_oo
- [1] Idorsia Ltd.. (3/18/24). "Press Release: Idorsia and Viatris Successfully Close the Transaction for the Global Research and Development Collaboration". Allschwil....
- [2] Idorsia Ltd.. (2/28/24). "Press Release: Idorsia and Viatris Enter into a Significant Global Research and Development Collaboration". Allschwil....
- [3] Santhera Pharmaceuticals Holding AG. (10/27/23). "Press Release: Santhera Receives U.S. FDA Approval of AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular Dystrophy [Ad hoc announcement pursuant to Art. 53 LR]". Pratteln....
- [4] Santhera Pharmaceuticals Holding AG. (6/20/23). "Press Release: Santhera Grants Exclusive North America License for Vamorolone to Catalyst Pharmaceuticals in Deal Valued at up to USD 231 Million Plus Royalties [Ad hoc announcement pursuant to Art. 53 LR]...
- [5] ObsEva S.A.. (11/22/22). "Press Release: ObsEva Announces Sale of Ebopiprant License Agreement to XOMA for up to $113 Million". Geneva....
- [6] Genfit S.A.. (9/19/22). "Press Release: Genfit to Acquire Clinical-stage Biopharmaceutical Company Versantis, Expanding Its Portfolio in Liver Diseases". Lille & Cambridge, MA....
- [7] Santhera Pharmaceuticals Holding AG. (1/4/22). "Press Release: Santhera Enters into Exclusive License Agreement with Sperogenix for Vamorolone in Rare Diseases in the Greater China Region". Pratteln....
- [8] Relief Therapeutics Holding AG. (11/30/21). "Press Release: Relief Therapeutics Announces Executive Changes". Geneva....
- [9] Santhera Pharmaceuticals Holding AG. (11/4/21). "Press Release: Santhera Appoints Stephanie Brown as President North America and Member of the Executive Management Team". Pratteln....
- [10] Idorsia Ltd.. (10/11/21). "Press Release: Idorsia Announces the Results of MODIFY, a Phase 3 Study of Lucerastat in Fabry Disease". Allschwil....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top